Biofrontera, Inc. (BFRI)

Over the past six months, Biofrontera, Inc. stock has been impacted by record revenues and improved financials in Q4 and full year 2025, the acquisition of U.S. Ameluz and RhodoLED assets, positive clinical trial results for Ameluz, FDA acceptance of the sNDA for Ameluz PDT for sBCC, a patent victory against Sun Pharma, the divestiture of Xepi, a revenue decline in Q3 2025, and stock price volatility.

While not explicitly detailed, there are indications that the fourth quarter is crucial for Biofrontera's revenue performance. The company reported record revenues in Q4 2025, suggesting a potential increase in demand or sales activity towards the end of the year. The company's strategy of expanding its sales force and favorable reimbursement policies are expected to attract new customers, which could influence demand patterns.

Biofrontera, Inc. is a U.S.-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions, primarily focusing on photodynamic therapy (PDT) and topical antibiotics. The company operates within the healthcare sector and the drug manufacturing industry, specifically focusing on specialty and generic drugs. Its major products include Ameluz, used with BF-RhodoLED lamps for photodynamic therapy to treat actinic keratoses, and Xepi, a topical antibiotic for impetigo, which has recently been divested.

Biofrontera, Inc. is headquartered in Woburn, Massachusetts, United States, with its primary focus for commercialization being the United States market.

Biofrontera's brand reputation in the past year appears to be generally positive, particularly within its niche in dermatology. Positive clinical developments, strategic business moves, financial performance, and patent protection contribute to its reputation as an innovative biopharmaceutical company.

Biofrontera, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold 20.07% of the stock, insiders own 25.83%, and retail investors hold 54.10%. Beteiligungen Aktiengesellschaft Vv is the largest individual shareholder, owning 3.94% of the company.